Competitive Pressure for First-in-Class Drugs is Intensifying
Study shows sharp reduction in market exclusivity periods for first-in-class treatment entrants.
Oncology Leads Personalized Medicine
Study finds that almost 75% of cancer drug candidates rely on biomarker data.
Between 2004 and 2012, the Number of Endpoints per Protocol has Nearly Doubled
Tufts CSDD
Survey Results of Start-Up Cycle Times